PHR

Rating neutralAI MemoPost-earnings T+1

Phreesia

As of 2026-09-03/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 FY2027 results reaffirm operating progress but miss adjusted EPS • 2026-09-02

Base target: $13 / p=50% prob

Biggest risk

The Q2 adjusted-EPS miss and roughly 10% immediate selloff show high sensitivity to execution. Network-solutions forecasting has limited second-half visibility, subscription revenue declined 2% under deliberate pricing moderation, and the restructuring plan involves approximately 220 eliminated positions and about $10 million of expected charges. Analyst estimate and target revisions after the print are unavailable.

Invalidation

Break below $9 or thesis failure.

What would change my mind?

Revenue growth, improving profitability, positive cash generation, debt reduction, and AccessOne/ProviderConnect expansion support a constructive medium-term case. The deterministic prior is positive, and the reported median analyst target of $13.9412 implies roughly 18% upside from the $11.85 anchor, though analyst-count coverage is unavailable.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-03

Base target

$13

p=50%

Bull target

$15

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print pressure from EPS miss and weak network visibility
AccessOne and ProviderConnect execution
Revenue growth, improving profitability, positive cash generation, debt reduction, and AccessOne/ProviderConnect expansion support a constructive medium-term case.

BearKey bullets

Adjusted EPS missed reported consensus despite a modest revenue beat.
Analyst revision data and social sentiment are unavailable, limiting confirmation of the post-earnings thesis.
Network-solutions revenue visibility is more variable in the second half of fiscal 2027.

WatchKey bullets

Q2 FY2027 results reaffirm operating progress but miss adjusted EPS

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $13 (p=50%)

Target spread vs base: +13% / -30%

Scenario probabilities

Bull Target: $15 (p=25%)Base Target: $13 (p=50%)Bear Target: $9 (p=25%)

Commentary

News tone is mixed: the primary release shows revenue, EBITDA, cash flow, and debt-paydown progress, while trusted coverage linked the immediate roughly 10% decline to the adjusted-EPS miss. Analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable; Form 4 activity consisted of director grants or acquisitions and is not operating evidence. The positive deterministic prior is offset by the elevated thesis-change signal and low coverage, favoring monitoring rather than an aggressive directional view.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print pressure from EPS miss and weak network visibility
AccessOne and ProviderConnect execution

Scenarios

Bull Target (Scenario probability)

$15 / p=25% prob

Base Target (Scenario probability)

$13 / p=50% prob

Bear Target (Scenario probability)

$9 / p=25% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-02
Q2 FY2027 results reaffirm operating progress but miss adjusted EPS
Phreesia reported Q2 revenue of $129.5 million, up 10% year over year, adjusted EBITDA of $32.9 million, positive free cash flow of $13.8 million, and debt principal reduction of more than $23 million. Management maintained FY2027 revenue guidance of $510-$520 million and adjusted EBITDA guidance of $125-$135 million. The primary release characterized results as in line with expectations. [#SEC-8K-2026-09-02] [#8-K-2026-09-02]
Prob 100.00% • Move -10.00% • Priced-in 100.00%

Short-term Catalysts

Next few weeks

Post-print pressure from EPS miss and weak network visibility
2026-09-30
Trusted market coverage reported adjusted EPS of $0.03 versus approximately $0.09 consensus, despite a modest revenue beat, with an immediate share-price decline of roughly 10%. Management also warned that network-solutions revenue forecasting is more variable, particularly in the second half of fiscal 2027. [Reuters via Investing.com](https://www.investing.com/news/earnings/phreesia-shares-tumble-10-on-second-quarter-earnings-miss-93CH-4886710) [#SEC-8K-2026-09-02]
Prob 70% • Move -8% • Priced-in 70%

Long-term Catalysts

Months to a year

AccessOne and ProviderConnect execution
2027-01-31
Management identified AccessOne and ProviderConnect as future growth drivers. Payment-solutions revenue grew 36% year over year, largely driven by AccessOne, while ProviderConnect was described as receiving a strong market response. AI investments are beginning to affect products and operations, but monetization remains an early-stage forward hook. [#SEC-8K-2026-09-02]
Prob 55% • Move 18% • Priced-in 35%

Risks

Adjusted EPS missed reported consensus despite a modest revenue beat.
Analyst revision data and social sentiment are unavailable, limiting confirmation of the post-earnings thesis.
Network-solutions revenue visibility is more variable in the second half of fiscal 2027.
Phreesia still reported $61 million of borrowings under its Capital One facility as of July 31, 2026.
Restructuring may create execution and employee-transition risk; approximately $10 million of charges are expected.
Subscription revenue declined 2% year over year as pricing is moderated to support downstream payment and network growth.

Peers

Symbol	Summary
ANGO	Similar market-cap sector candidate, but AngioDynamics is a medical-device company rather than a healthcare software, payments, and network-solutions platform; valuation comparison is limited.
KIDS	Similar market-cap sector candidate, but OrthoPediatrics is an orthopedic-device issuer with materially different growth, margin, and reimbursement drivers; use only as a loose sector reference.
BSX	Large-scale cardiovascular-device benchmark useful for broad healthcare-equipment sentiment, but not a direct business-model peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

ANGO

Similar market-cap sector candidate, but AngioDynamics is a medical-device company rather than a healthcare software, payments, and network-solutions platform; valuation comparison is limited.

KIDS

Similar market-cap sector candidate, but OrthoPediatrics is an orthopedic-device issuer with materially different growth, margin, and reimbursement drivers; use only as a loose sector reference.

BSX

Large-scale cardiovascular-device benchmark useful for broad healthcare-equipment sentiment, but not a direct business-model peer.